

# Laguna Hills

---

## Clinical Research Treatment Trial Flowchart

**MYELOPROLIFERATIVE NEOPLASM: FRONT LINE**

**ETCTN 10538**

Venetoclax+ASTX727 (All oral therapy) for CMML, PDS/MPN with excess blasts

Mechanism: BCL-2 selective inhibitor

PI: Jeyakumar  
 Coord: S. Osorio  
 Accrual: 0/5

**NEWLY DIAGNOSED: HIGH RISK**

**ETCTN 10612**

Daratumumab-Selinexor-Velcade-Dexamethasone (Dara-SVD) vs Daratumumab, Lenalidomide, Velcade, and Dexamethasone (Dara-RVD)

Mechanism: selective inhibitor of nuclear export (SINE) compound + IgG1κ monoclonal antibody (mAb) + proteasome inhibitor

PI: Lee  
 Coord: H. Mehrok  
 Accrual: 0/5

■ Open to Accrual ■ Low Accruing ■ Pending Activation/Suspended

**CLL RELAPSED/REFRACTORY: 2L+**

**UCI 21-209**

LOXO-305 + Venetoclax and Rituximab vs. Venetoclax and Rituximab in previously treated CLL/SLL

Mechanism: BTK inhibitor + BCL2 inhibitor + CD20 marker

PI: Coombs  
 Coord: A. Saatchi  
 Accrual: 2/3

**CLL NEWLY DIAGNOSED: HIGH RISK**

**SWOG S1925**

Venetoclax+Obnutumab early intervention vs. delayed therapy in asymptomatic high-risk CLL/SLL

Mechanism: BCL2 inhibitor +anti-CD20 monoclonal antibody

PI: Coombs  
 Coord: A. Saatchi  
 Accrual: 1/10

CRC: ADJUVANT

NRG G1008/CIRCULATE

(ctDNA guided tx)

PI: Zell

Coord: A. Luna

Accrual: 1/5

MELANOMA: NON-TREATMENT

UCI 19-135

DecisionDx-Melanoma Impact on Sentinel Lymph Node Biopsy Decisions and Clinical Outcomes (DECIDE)

PI: Yamamoto  
Coord: A. Reipolska  
Accrual: 76/90